OakChart

Regenxbio Inc

RGNXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

8.47+0.78 (10.14%)
2026-11-12 06:15 CET
Market cap
560.06 USD m
Revenue, TTM
153.91 USD m
Net income, TTM
-175.23 USD m
Free cash flow, TTM
-154.80 USD m
EPS diluted, TTM
-3.21
P/E
-
Compare

Price

RGNX against its 20, 50 and 200-day averages
2050200beatmiss
5.007.5010.0012.5015.005.2M10.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RGNXclose 8.4720-day 7.3250-day 7.72200-day 8.918.4752w high52w low

47.7% under the 52-week high of 16.19 on 22 Jan 2026. 52-week low 5.46 on 18 May 2026. Last 15 sessions, 37.5% high to low

Volume 1.35× normal · the line is the 50-bar volume average

Profile

RGNX
52-week range, 28% of the way up
5.4516.19

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

IndexRUT
Employees371
IPOSep 17, 2015
Beta1.21
ATR, 14d0.59
Rel volume1.35
Short float16.64%
Insider own7.51%
Inst own64.32%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap560.06M
Enterprise Value561.08M
Income-175.23M
Sales153.91M
Book/sh2.24
Cash/sh3.80
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees371
IPOSep 17, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S3.64
P/B3.78
P/C2.23
P/FCF-
EV/EBITDA-
EV/Sales3.65
Quick Ratio4.74
Current Ratio4.74
Debt/Eq1.70
LT Debt/Eq1.58
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.21
EPS next Y-2.75
EPS next Q-0.96
EPS this Y22.92%
EPS next Y4.97%
EPS next 5Y24.36%
EPS past 3/5Y16.67% -4.73%
Sales past 3/5Y14.78% 1.97%
EPS Y/Y TTM8.03%
Sales Y/Y TTM-4.59%
EPS Q/Q47.91%
Sales Q/Q-69.19%
EarningsNov 05 BMO
EPS/Sales Surpr.51.84% -15.87%

Ownership

Insider Own7.51%
Insider Trans0.58%
Inst Own64.32%
Inst Trans4.77%
ROA-35.36%
ROE-113.24%
ROIC-45.91%
Gross Margin77.79%
Oper. Margin-120.39%
Profit Margin-113.85%
SMA2015.70%
SMA509.73%
SMA200-4.96%
Trades-

Technical

Shs Outstand66.12M
Shs Float61.16M
Short Float16.64%
Short Ratio7.45
Short Interest10.18M
52W High16.19 -47.68%
52W Low5.45 55.27%
Volatility10.66% 7.29%
ATR (14)0.59
RSI (14)61.07
Beta1.21
Rel Volume1.35
Avg Volume1.37M
Volume1,845,121

Performance

Perf Week9.86%
Perf Month16.67%
Perf Quarter-20.54%
Perf Half Y-15.64%
Perf YTD-41.18%
Perf Year-26.67%
Perf 3Y-52.52%
Perf 5Y-77.44%
Perf 10Y-63.65%
Recom1.36
Target Price22.36
Prev Close7.69
Price8.47
Change %10.14%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 05, 2026InitiatedMMizuhoOutperform$22+159.7%
Aug 07, 2026DowngradeBBarclaysOverweight → Equal Weight$12+41.7%
Jan 28, 2026ResumedBBarclaysOverweight$37+336.8%
Feb 11, 2025DowngradeGGoldmanBuy → Neutral$38 → $14+65.3%
Feb 07, 2025ResumedRRaymond JamesOutperform$27+218.8%
Nov 15, 2024ResumedMMorgan StanleyOverweight$22+159.7%
Oct 10, 2024ResumedRRaymond JamesOutperform$18+112.5%
Jun 07, 2024InitiatedGGoldmanBuy$38+348.6%
Mar 11, 2024InitiatedHH.C. WainwrightBuy$36+325.0%
Mar 08, 2024UpgradeRRBC Capital MktsSector Perform → Outperform$20 → $35+313.2%

Peers

Mkt cap
TickerCompanyMkt cap
SLDBSolid Biosciences Inc848.24M
SRPTSarepta Therapeutics Inc1.79B
FDMT4D Molecular Therapeutics Inc717.62M
RAREUltragenyx Pharmaceutical Inc1.70B
DNLIDenali Therapeutics Inc3.16B
QUREuniQure NV1.72B
RCKTRocket Pharmaceuticals Inc272.24M
DYNDyne Therapeutics Inc3.37B
TSHATaysha Gene Therapies Inc1.39B
OCGNOcugen Inc325.87M

Insider trading

13 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Ciongoli Gregory AustinDirectorAug 27 '26Buy9.3653,407499,676118,035Aug 27 07:03 PM
Ciongoli Gregory AustinDirectorAug 26 '26Buy9.1449,196449,70664,628Aug 27 07:03 PM
PAKOLA STEVEChief Medical OfficerJul 02 '26Option Exercise7.862,16116,985215,170Jul 06 04:51 PM
PAKOLA STEVEChief Medical OfficerJul 02 '26Sale13.642,16129,476213,009Jul 06 04:51 PM
PAKOLA STEVEChief Medical OfficerJul 01 '26Option Exercise7.8636,725288,658249,734Jul 01 08:08 PM
PAKOLA STEVEChief Medical OfficerJul 01 '26Sale12.8636,725472,284213,009Jul 01 08:08 PM
PAKOLA STEVEChief Medical OfficerJun 29 '26Sale11.0419,608216,472213,009Jul 01 08:08 PM
Stephen J. PakolaOfficerJul 01 '26Proposed Sale11.9843,206517,608Jul 01 04:30 PM
PAKOLA STEVEChief Medical OfficerMay 11 '26Sale11.0215,309168,705232,617May 13 05:18 PM
STEPHEN PAKOLAOfficerMay 11 '26Proposed Sale10.5534,917368,374May 11 04:36 PM
PAKOLA STEVEChief Medical OfficerMar 10 '26Sale10.355,12453,033247,926Mar 12 06:17 PM
STEPHEN J PAKOLAOfficerMar 10 '26Proposed Sale10.385,12453,187Mar 10 04:36 PM
Mills Kenneth T.DirectorJan 27 '26Option Exercise13.09225,0002,945,250707,871Jan 29 04:58 PM

Held by

AUM
TickerCompanyAUM
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IBBiShares Biotechnology ETFAUM: 11.36B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 198

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.620-1.287-0.6209.1610.8911
2026Q22026-08-060.4300.0790.428108.0297.6311
2026Q12026-05-14-1.720-1.337-1.7186.3925.8410
2025Q42026-03-05-1.300-0.956-1.29830.3443.9612
2025Q32025-11-06-1.200-1.282-1.19829.7324.8212
2025Q22025-08-07-1.380-0.938-1.37721.3638.7012
2025Q12025-05-120.1200.4600.11889.01107.8912
2024Q42025-03-13-1.010-1.141-1.03321.2123.7010
2024Q32024-11-06-1.170-1.122-1.17324.2023.639
2024Q22024-08-01-1.050-1.292-1.04722.3022.978
2024Q12024-05-08-1.380-1.259-1.38515.6223.5210
2023Q42024-02-27-1.430-1.270-1.42922.2134.019
2023Q32023-11-08-1.410-1.457-1.40828.9126.1410
2023Q22023-08-02-1.660-1.187-1.65519.9834.509
2023Q12023-05-03-1.530-1.421-1.53519.1431.228
2022Q42023-02-28-1.380-1.283-1.38431.3537.458

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.580-2.394-2.58235.2353.96
2020FY-2.980-2.853-2.984154.57159.42
2021FY2.7403.8922.911470.35492.16
2022FY-6.500-6.190-6.496112.72120.42
2023FY-6.020-5.516-6.02590.24118.32
2024FY-4.590-4.726-4.58783.3386.91
2025FY-3.760-3.305-3.760170.44184.6
2026FY--2.898--151.76
2027FY--2.754--194.38
2028FY--1.627--351.96
2029FY-0.553--560.63
2030FY-3.195--816.54

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0694128.326.60179.1
2026Q4S2026-11-0593127.866.60179.1
2026Q4S2026-10-2992126.206.29161
2026Q4S2026-10-28102132.876.29161
2026Q4S2026-10-27102132.876.30161
2026Q4S2026-10-21102132.876.29161
2026Q4S2026-10-20103232.876.29161
2026Q4S2026-10-09105432.876.29161
2026Q4S2026-10-02103532.826.00161
2026Q4S2026-08-2493535.807.00161
2026Q4S2026-08-2193540.027.00161
2026Q4S2026-08-0793540.037.00161
2026Q4S2026-08-0692441.517.02161
2026Q4S2026-07-2891261.927.00143.3

Estimate history

EPS, annual-2.4492.727-2.582-2.9842.911-6.496-6.025-4.587-3.759-3.211
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.173-1.0330.118-1.377-1.198-1.298-1.7180.428-0.624
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual10.393218.50535.233154.567470.347112.72490.24283.328170.441153.91
Period201720182019202020212022202320242025TTM
Sales, quarterly24.19721.21489.01221.35929.73330.3376.393108.0199.162
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual31.29536.1236.99237.47642.83143.29944.04649.54950.89266.119
Period201720182019202020212022202320242025MRQ
Shares, quarterly49.53449.54950.11750.38950.61950.89251.61754.16466.119
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue153.91170.4483.3390.24112.72470.35154.5735.23218.50
Cost of Goods Sold Incl. D&A34.1835.9149.7854.5367.4561.4044.1215.3913.62
Gross Profit119.73134.5333.5535.7145.27408.95110.4519.84204.88
Selling, General and Administrative Excl. Other304.93295.55268.93303.44314.82251.21221.70168.85116.74
Research and Development219.05212.68192.31214.95229.54171.87157.89117.0383.87
Other Operating Expense0.100.18-4.130.40-6.68-2.247.97-0.010.04
Operating Income-185.29-161.20-231.25-268.13-262.88159.98-119.23-149.0088.10
Interest Expense36.2545.0112.666.8623.2526.280.770.00-
Unusual Expense-38.030.002.100.00-0.000.00-31.78-
Net Income Before Taxes-175.23-193.88-227.10-263.65-280.40141.25-106.01-97.49104.12
Income Taxes0.000.000.00-0.15-0.0813.415.24-2.754.18
Consolidated Net Income-175.23-193.88-227.10-263.49-280.32127.84-111.25-94.7399.94
Net Income From Continuing Operations-175.23-193.88-227.10-263.49-280.32127.84-111.25-94.7399.94
Net Income-175.23-193.88-227.10-263.49-280.32127.84-111.25-94.7399.94
EPS (Recurring)-3.09-3.76-4.56-6.02-6.502.91-2.98-3.192.73
EPS (Basic, Before Extraordinaries)-3.21-3.76-4.59-6.02-6.503.01-2.98-2.582.99
EPS (Diluted)-3.21-3.76-4.59-6.02-6.502.91-2.98-2.582.73
EBITDA-170.30-145.58-215.03-250.81-249.97169.54-110.83-141.8592.08
Non-Operating Income (Expense)8.2912.3318.9011.345.727.5413.9919.7316.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense34.1634.5638.4631.8132.2228.3323.3219.6013.15
Price To Earnings Ratio----14.5711.91--14.54
Price To Sales Ratio3.194.364.598.708.683.0510.9442.667.04
Gross Margin77.7978.9340.2639.5740.1686.9571.4656.3193.77
Operating Margin-120.39-94.58-277.51-297.12-233.2034.01-77.14-422.8940.32
Net Margin-113.85-113.75-272.54-291.99-248.6827.18-71.98-268.8845.74
Shares Outstanding66.1250.8949.5544.0543.3042.8337.4836.9936.12
Market Capitalization560.06560.06382.98789.66981.901,398.551,696.851,510.731,503.49

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue9.16108.026.3930.3429.7321.3689.0121.21
Cost of Goods Sold Incl. D&A4.664.8014.939.809.619.117.3910.34
Gross Profit4.51103.22-8.5420.5420.1212.2481.6210.87
Selling, General and Administrative Excl. Other78.0773.9474.7978.1272.4775.4869.4866.41
Research and Development57.4952.3353.4855.7452.2255.5949.1346.36
Other Operating Expense-0.010.010.040.050.070.040.01-4.17
Operating Income-73.5629.26-83.36-57.64-52.41-63.2812.13-51.37
Interest Expense7.477.798.7112.2813.1710.998.579.42
Unusual Expense-38.030.000.000.000.000.000.000.00
Net Income Before Taxes-40.7422.71-90.05-67.15-61.94-70.876.08-51.19
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-40.7422.71-90.05-67.15-61.94-70.876.08-51.19
Net Income From Continuing Operations-40.7422.71-90.05-67.15-61.94-70.876.08-51.19
Net Income-40.7422.71-90.05-67.15-61.94-70.876.08-51.19
EPS (Recurring)-1.030.43-1.72-1.30-1.20-1.380.12-1.03
EPS (Basic, Before Extraordinaries)-0.620.43-1.72-1.30-1.20-1.380.12-1.03
EPS (Diluted)-0.620.43-1.72-1.30-1.20-1.380.12-1.03
EBITDA-70.0533.02-79.50-53.77-48.52-59.3716.08-47.34
Non-Operating Income (Expense)2.271.242.022.763.643.402.539.60
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.129.058.628.389.008.658.549.54
Price To Sales Ratio3.193.645.004.373.092.712.354.60
Gross Margin49.1895.56-133.5567.7167.6857.3391.7051.25
Operating Margin-802.8827.09-1,303.96-189.99-176.27-296.2613.62-242.14
Net Margin-444.6421.02-1,408.59-221.34-208.32-331.816.83-241.28
Shares Outstanding66.1254.1651.6250.8950.6250.3950.1249.55
Market Capitalization560.06619.34432.52728.97487.46413.69358.12382.98

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments230.07234.69275.26364.64457.44475.74296.21319.76160.78
Short Term Receivables27.3821.5726.3428.0832.4443.0038.158.590.47
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets23.8321.7533.3723.2528.9512.4610.679.566.75
Total Current Assets281.28278.00334.97415.98518.83531.20345.03337.91168.00
Net Property, Plant & Equipment152.01171.31192.59206.80192.45120.2839.0528.7013.98
Total Investments and Advances12.8112.2140.90202.59393.9448.14105.11152.2716.24
Long-Term Note Receivable2.310.470.701.502.263.274.1623.01-
Other Assets4.614.004.816.406.435.284.551.920.46
Total Assets453.03465.99573.97833.271,113.90708.16497.91543.81198.68
Short Term Debt Incl. Current Port. of LT Debt47.9042.217.076.001.752.502.420.000.00
Accounts Payable21.3622.8022.7927.2111.3910.626.414.414.83
Income Tax Payable---0.0011.323.130.000.73-
Other Current Liabilities48.8438.19100.4297.22106.0165.1924.8517.049.61
Total Current Liabilities118.09103.19130.27130.43130.4781.4533.6822.1814.44
Long Term Debt212.6299.5182.2288.8084.9370.158.875.850.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities19.583.6349.7397.84134.21178.815.166.941.21
Total Liabilities350.30206.34262.23317.07349.61330.4147.7134.9715.65
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity102.73259.65311.74516.20764.30377.75450.20508.85183.03
Total Shareholders Equity102.73259.65311.74516.20764.30377.75450.20508.85183.03
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity102.73259.65311.74516.20764.30377.75450.20508.85183.03
Total Liabilities & Stockholders Equity453.03465.99573.97833.271,113.90708.16497.91543.81198.68
Book Value Per Share2.025.247.0811.9217.8410.0812.1714.095.85
Tangible Book Value Per Share2.025.247.0811.9217.8410.0812.1714.095.85
Full-Time Employees371353344401372306257192139
Price to Book Ratio3.781.272.171.741.834.503.372.985.31
Return on Assets-42.19-43.68-37.45-28.7914.03-18.45-18.1926.92-39.40
Return on Equity-107.00-79.49-63.65-43.7822.39-26.87-19.7628.89-42.45
Return on Invested Capital-61.48-63.23-66.88-46.3315.05-24.84-20.6419.42-39.98
Quick Ratio2.382.692.573.193.986.5210.2515.2411.64
Current Ratio2.382.692.573.193.986.5210.2515.2411.64

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-175.23-193.88-227.10-263.49-280.32127.84-111.25-94.7399.94
Depreciation15.0015.6216.2117.3212.919.568.417.153.98
Other Funds (Non Cash)52.7942.5232.2338.6545.9541.2534.56-14.808.50
Funds from Operations-107.44-135.74-178.66-207.52-221.47178.66-68.28-102.38112.42
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-44.6711.785.53-10.8913.9840.2214.22-5.33-7.77
Cash from Operating Activities-152.10-123.96-173.12-218.41-207.49218.88-54.06-107.70104.65
Capital Expenditures-2.70-2.41-2.44-9.96-30.72-84.17-26.87-11.72-13.28
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments90.59-13.45105.88200.9018.80-322.47149.63105.28-266.08
Purchase of Investments-201.51-332.63-190.14-86.56-184.88-498.14-123.04-190.74-445.83
Sale Or Maturity of Investments292.11319.18296.02287.47203.67175.68272.67296.01179.75
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities87.90-15.87103.45190.94-11.93-406.64122.7693.56-279.36
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-15.361.01133.457.754.55222.117.428.38204.44
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-15.361.01133.457.754.55222.117.428.38204.44
Proceedsfrom Stock Options19.920.69131.946.231.74217.831.801.31189.94
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00-
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00-
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00-
Net Financing Active Other Cash Flow116.56115.76-40.76-42.72-33.39-26.86192.790.000.00
Other Financing Activities Uses-27.93-28.73-40.76-42.72-33.39-26.86-3.210.000.00
Cash from Financing Activities101.20116.7792.68-34.97-28.84195.25200.218.38204.44
Net Change in Cash36.99-23.0623.00-62.43-248.267.48268.91-5.7729.73
Free Cash Flow-154.80-126.38-175.56-228.37-238.21134.70-80.93-119.4291.37
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-----10.66--16.83
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments251.20105.74150.49230.07274.20323.30
Short Term Receivables9.50107.1010.9427.3826.4721.49
Inventories0.000.000.000.000.000.00
Other Current Assets60.1923.3125.0923.8331.3028.97
Total Current Assets320.89236.16186.52281.28331.97373.75
Net Property, Plant & Equipment137.59142.32147.41152.01156.34161.49
Total Investments and Advances1.801.802.0312.8129.8742.33
Other Assets5.305.905.514.614.271.88
Total Assets466.04386.62341.89453.03525.20581.03
Short Term Debt Incl. Current Port. of LT Debt18.6134.1222.0947.9050.7948.35
Accounts Payable13.4815.5521.2121.3622.2721.66
Other Current Liabilities35.6032.9527.8148.8451.5149.53
Total Current Liabilities67.6882.6271.11118.09124.57119.54
Long Term Debt233.62216.34226.30212.62217.35223.34
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities16.7015.8923.4019.5821.8324.47
Total Liabilities318.00314.85320.81350.30363.75367.35
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity148.0471.7721.08102.73161.45213.68
Total Shareholders Equity148.0471.7721.08102.73161.45213.68
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity148.0471.7721.08102.73161.45213.68
Total Liabilities & Stockholders Equity466.04386.62341.89453.03525.20581.03
Book Value Per Share2.241.320.412.023.194.24
Tangible Book Value Per Share2.241.320.412.023.194.24
Full-Time Employees---371--
Price to Book Ratio3.7829.334.154.512.281.50
Return on Assets-35.36-40.60-69.65-42.19-34.07-30.52
Return on Equity-113.24-137.63-196.43-107.00-76.88-62.49
Return on Invested Capital-10.677.88-36.40-21.29-16.35-16.22
Quick Ratio4.742.862.622.382.663.13
Current Ratio4.742.862.622.382.663.13

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-40.7422.71-90.05-67.15-61.94-70.87
Depreciation3.523.763.863.873.893.90
Other Funds (Non Cash)13.9214.5811.5112.7912.4710.09
Funds from Operations-23.3041.04-74.68-50.49-45.59-56.88
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital61.91-103.28-1.50-1.80-10.377.54
Cash from Operating Activities38.61-62.24-76.19-52.29-55.96-49.34
Capital Expenditures-0.19-0.76-1.24-0.51-0.49-0.39
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-85.9666.6971.8238.0542.78-140.04
Purchase of Investments-128.870.00-9.84-62.81-39.52-211.14
Sale Or Maturity of Investments42.9166.6981.66100.8682.3071.10
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-86.1565.9270.5937.5442.29-140.44
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock109.1219.380.56-144.43145.16-0.03
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock109.1219.380.56-144.43145.16-0.03
Proceedsfrom Stock Options-0.2019.33-0.231.02-0.38-0.11
Issuance or Reduction of Debt, Net0.000.000.000.00-144.53144.53
Change in Long Term Debt0.000.000.000.00-144.53144.53
Issuance of Long Term Debt0.000.000.000.00-144.53144.53
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-2.27-1.81-14.20134.84-7.72-5.26
Other Financing Activities Uses-2.27-1.81-14.20-9.65-7.72-5.26
Cash from Financing Activities106.8517.57-13.64-9.58-7.08139.23
Net Change in Cash59.3121.26-19.24-24.34-20.76-50.55
Free Cash Flow38.41-63.00-77.42-52.80-56.45-49.73

Revenue breakdown

License and Service2024: 81.96M 2025: 156.27M
Service2024: 1.37M 2025: 14.17M
United States2024: 83.33M 2025: 170.44M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.64%10.2M61.2M1.35M
2026-10-1516.45%10.0M61.1M1.48M
2026-09-3015.74%9.6M61.1M1.66M
2026-09-1512.98%7.9M61.1M1.94M
2026-08-3112.29%7.5M61.0M1.98M
2026-08-1413.52%8.2M60.7M2.07M
2026-07-3112.15%7.2M59.2M2.22M
2026-07-1518.56%8.6M46.5M1.98M
2026-06-3022.37%10.5M46.8M1.63M
2026-06-1519.82%9.3M46.7M1.23M
2026-05-2917.72%8.3M46.7M1.19M
2026-05-1515.22%7.1M46.9M1.04M
2026-04-3014.53%6.7M46.1M822.64K
2026-04-1515.08%6.9M46.1M962.77K
2026-03-3114.60%6.7M46.0M995.07K
2026-03-1314.08%6.5M46.0M975.64K
2026-02-2713.90%6.4M46.0M888.52K
2026-02-1313.31%6.0M45.1M869.53K
2026-01-3010.70%4.9M45.6M787.98K
2026-01-1511.24%5.1M45.6M648.76K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.005.509.000.000.0000.000.000.991-0.0150.000
call2.004.508.000.0019.8270.000.000.977-0.0250.001
call3.003.507.003.8212.97322.000.000.967-0.0250.001
call4.002.506.004.229.75715.000.000.927-0.0450.002
call5.001.505.500.009.2930.000.000.894-0.0480.002
call6.000.504.902.508.51325.000.000.857-0.0440.003
call7.000.304.900.759.38115.000.000.799-0.0370.004
call8.000.002.000.703.47060.000.000.785-0.2110.004
call9.000.805.000.812.30781021.000.571-0.1070.005
call10.000.350.950.502.42742450.000.402-0.0700.005
call11.000.001.000.502.89725.000.000.362-0.0810.005
call12.000.000.500.332.6901.000.000.276-0.0680.004
call13.000.001.650.003.0720.000.000.256-0.0740.004
call14.000.004.900.003.3580.000.000.242-0.0780.004
call15.000.004.900.053.61317.000.000.231-0.0820.004
call16.000.004.900.105.1061.000.000.326-0.1280.005
put1.000.000.050.007.2360.000.00-0.010-0.0130.000
put2.000.004.900.005.9240.000.00-0.024-0.0240.001
put3.000.002.100.004.4740.000.00-0.033-0.0240.001
put4.000.002.250.154.32210.000.00-0.073-0.0450.002
put5.000.000.500.004.3060.000.00-0.167-0.0690.003
put6.000.000.950.503.15034.000.00-0.229-0.0610.004
put7.000.000.600.551.7612610.00-0.201-0.0370.004
put8.000.004.902.0711.3794.000.00-0.215-0.2100.004
put9.000.104.902.829.3084.000.00-0.429-0.1060.005
put10.000.304.900.007.5810.000.00-0.598-0.0690.005
put11.001.004.901.256.0395.000.00-0.638-0.0800.005
put12.002.006.004.656.6432.000.00-0.725-0.0670.004
put13.003.007.006.007.0010.000.00-0.744-0.0720.004
put14.004.007.500.006.3640.000.00-0.758-0.0770.004
put15.005.008.500.006.6520.000.00-0.769-0.0810.004
put16.006.009.500.006.9120.000.00-0.777-0.0840.004

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-10-168-KCurrent report2026-10-14SEC
2026-10-13SCHEDULE 13GSEC
2026-09-238-KCurrent report2026-09-23SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-273Initial statement of beneficial ownership of securities2026-08-25SEC
2026-08-258-KCurrent report2026-08-25SEC
2026-08-248-KCurrent report2026-08-24SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-01SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-01SEC
2026-07-208-KCurrent report2026-07-16SEC
2026-07-17424B5SEC
2026-07-17FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-07-16424B5SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-064Statement of changes in beneficial ownership of securities2025-12-31SEC
2026-07-06SC TO-I/ASEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-01SC TO-I/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08949.38K200
2026-0700501.76K2
2026-0600216.47K1
2026-0500168.71K1
2026-040000
2026-030053.03K1
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.12.37%
Redmile Group, LLC8.45%
STATE STREET CORP5.75%
JPMORGAN CHASE & CO4.28%
VANGUARD CAPITAL MANAGEMENT LLC4.08%
MORGAN STANLEY3.78%
GOLDMAN SACHS GROUP INC2.75%
AQR CAPITAL MANAGEMENT LLC2.67%
VANGUARD PORTFOLIO MANAGEMENT LLC2.62%
MARSHALL WACE, LLP2.49%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.79%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.89%
iShares Russell 2000 ETF2.46%
Nuveen Quant Small Cap Equity Fund1.31%
JPMorgan Small Cap Growth Fund1.22%
VANGUARD EXTENDED MARKET INDEX FUND1.09%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND0.90%
BlackRock Advantage Small Cap Core Fund0.81%
Fidelity Small Cap Index Fund0.81%
iShares Russell 2000 Growth ETF0.73%

OakChart. RGNX. Cached 15 minutes.